NYSEAMERICAN:STXS Stereotaxis (STXS) Stock Price, News & Analysis $2.04 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.98▼$2.0650-Day Range N/A52-Week Range$1.33▼$3.29Volume142,642 shsAverage Volume336,132 shsMarket Capitalization$168.59 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipShort Interest Get Stereotaxis alerts: Email Address Stereotaxis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside120.6% Upside$4.50 Price TargetShort InterestBearish4.38% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.33Based on 2 Articles This WeekInsider TradingAcquiring Shares$26,440 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.21) to ($0.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.35 out of 5 stars 3.5 Analyst's Opinion Consensus RatingStereotaxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageStereotaxis has received no research coverage in the past 90 days.Read more about Stereotaxis' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.38% of the float of Stereotaxis has been sold short.Short Interest Ratio / Days to CoverStereotaxis has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Stereotaxis has recently increased by 91.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldStereotaxis does not currently pay a dividend.Dividend GrowthStereotaxis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for STXS. Previous Next 1.5 News and Social Media Coverage News SentimentStereotaxis has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Stereotaxis this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Stereotaxis to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stereotaxis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $26,440.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders18.52% of the stock of Stereotaxis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.35% of the stock of Stereotaxis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Stereotaxis' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Stereotaxis are expected to grow in the coming year, from ($0.21) to ($0.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stereotaxis is -7.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stereotaxis is -7.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStereotaxis has a P/B Ratio of 10.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About Stereotaxis Stock (NYSEAMERICAN:STXS)Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.Read More STXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STXS Stock News HeadlinesJuly 22, 2024 | globenewswire.comStereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024July 18, 2024 | globenewswire.comStereotaxis Strengthens Board of Directors with Appointment of Nachum ShamirJuly 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…May 29, 2024 | globenewswire.comPenn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart TreatmentMay 24, 2024 | finance.yahoo.comStereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory FrameworkMay 24, 2024 | globenewswire.comStereotaxis Receives CE Mark Recertification Under EU's MDR Regulatory FrameworkMay 23, 2024 | seekingalpha.comStereotaxis Makes A Strategic Acquisition Bolstering Its FutureMay 22, 2024 | globenewswire.comFirst Heart Rhythm Patients in Southern Italy Treated with Advanced Robotic TechnologyJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.May 15, 2024 | globenewswire.comStereotaxis Invited by Africa Heart Rhythm Association to Present its Innovative Robotic Solution to Expand High-Quality Therapy in Underserved Regions of AfricaMay 14, 2024 | finanznachrichten.deStereotaxis, Inc.: Stereotaxis Reports 2024 First Quarter Financial ResultsMay 14, 2024 | finanznachrichten.deStereotaxis, Inc.: Stereotaxis Announces Definitive Agreement to Acquire Access Point TechnologiesMay 14, 2024 | msn.comStereotaxis, Inc. (AMEX:STXS) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comStereotaxis Inc (STXS) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth and ChallengesMay 13, 2024 | investorplace.comSTXS Stock Earnings: Stereotaxis Meets EPS, Misses Revenue for Q1 2024May 13, 2024 | bizjournals.comSt. Louis public company to acquire medical manufacturerMay 13, 2024 | marketwatch.comStereotaxis To Acquire Access Point TechnologiesMay 13, 2024 | globenewswire.comStereotaxis Reports 2024 First Quarter Financial ResultsSee More Headlines Receive STXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stereotaxis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNYSEAMERICAN:STXS CUSIPN/A CIKN/A Webwww.stereotaxis.com Phone(314) 678-6100Fax314-678-6159Employees122Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+125.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,710,000.00 Net Margins-73.32% Pretax Margin-73.32% Return on Equity-111.94% Return on Assets-45.63% Debt Debt-to-Equity RatioN/A Current Ratio2.43 Quick Ratio1.79 Sales & Book Value Annual Sales$26.77 million Price / Sales6.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book10.00Miscellaneous Outstanding Shares82,640,000Free Float67,338,000Market Cap$165.28 million OptionableNot Optionable Beta1.52 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. David Leo Fischel C.A.I.A. (Age 37)C.F.A., C.P.A., M.B.A., CEO & Chairman Comp: $62.2kMs. Kimberly R. Peery (Age 55)CFO & Secretary Comp: $251.76kMr. Keith GallowayVice President of OperationsMs. Laura Spencer GarthGeneral Counsel & SecretaryMr. Guy JudkowskiEquity Portfolio ManagerKey CompetitorsAxoGenNASDAQ:AXGNZynexNASDAQ:ZYXISemler ScientificNASDAQ:SMLROutset MedicalNASDAQ:OMEdap TmsNASDAQ:EDAPView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 135,041 shares on 7/26/2024Ownership: 0.229%Paul J IsaacBought 7,000 shares on 6/14/2024Total: $13,020.00 ($1.86/share)Paul J IsaacBought 1,000 shares on 5/31/2024Total: $1,960.00 ($1.96/share)Paul J IsaacBought 6,000 shares on 5/28/2024Total: $11,460.00 ($1.91/share)Virtu Financial LLCBought 11,739 shares on 5/20/2024Ownership: 0.040%View All Insider TransactionsView All Institutional Transactions STXS Stock Analysis - Frequently Asked Questions How have STXS shares performed this year? Stereotaxis' stock was trading at $2.87 at the start of the year. Since then, STXS stock has decreased by 28.9% and is now trading at $2.04. View the best growth stocks for 2024 here. How were Stereotaxis' earnings last quarter? Stereotaxis, Inc. (NYSEAMERICAN:STXS) released its quarterly earnings data on Monday, May, 13th. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.01. The business earned $6.88 million during the quarter, compared to analysts' expectations of $7.10 million. Stereotaxis had a negative trailing twelve-month return on equity of 111.94% and a negative net margin of 73.32%. Who are Stereotaxis' major shareholders? Top institutional investors of Stereotaxis include Bank of New York Mellon Corp (0.23%). View institutional ownership trends. How do I buy shares of Stereotaxis? Shares of STXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:STXS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stereotaxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Stereotaxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
